Genenta Science SpA ADR - Asset Resilience Ratio
Genenta Science SpA ADR (GNTA) has an Asset Resilience Ratio of 70.94% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Genenta Science SpA ADR's Asset Resilience Ratio has changed over time. Check Genenta Science SpA ADR strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Genenta Science SpA ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GNTA company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $22.62 Million | 70.94% |
| Total Liquid Assets | $22.62 Million | 70.94% |
Asset Resilience Insights
- Very High Liquidity: Genenta Science SpA ADR maintains exceptional liquid asset reserves at 70.94% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Genenta Science SpA ADR Industry Peers by Asset Resilience Ratio
Compare Genenta Science SpA ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Genenta Science SpA ADR (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Genenta Science SpA ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 70.94% | $22.62 Million | $31.89 Million | +16.44pp |
| 2024-12-31 | 54.49% | $8.08 Million | $14.82 Million | -13.01pp |
| 2023-12-31 | 67.50% | $15.08 Million | $22.35 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $33.44 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $40.03 Million | -- |
About Genenta Science SpA ADR
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for us… Read more